PMID: 9550282Jan 1, 1997Paper

Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice

Autoimmunity
V K RamiyaN K Maclaren

Abstract

Islet cell antigens have been administered orally and intravenously (I.V.) to NOD mice to assess their abilities to protect from or delay the onset of diabetes, and thereby provide insights that may have therapeutic implications in human trials. Whereas we and others have observed a delay in the onset of diabetes in NOD mice that have been fed with insulin from early life, we report here for the first time that feedings with porcine GAD65 alone (p = 0.226) or in combination with insulin (p = 0.011), have anti-diabetic effects in a prolonged study period (>400 days). While antigen-specific inhibitions of in vitro lymphocytic proliferation responses were seen (p < 0.05), antibody levels were unaffected by oral antigen treatments. IFN-gamma mRNA levels were downregulated in the islet infiltrates following oral antigen treatments while IL-2 and TNF-beta were expressed in all instances. We also observed that I.V. human recombinant GAD65, and porcine GAD given at weaning, delayed diabetes onset (p = 0.004) while similar treatments with a variety of inactive insulin preparations were generally ineffective. These findings thus indicate varying effects of oral and I.V. autoantigen administrations on the development of diabetes in NOD mi...Continue Reading

References

Feb 1, 1991·The Journal of Clinical Investigation·I L CampbellL C Harrison
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·Z J ZhangH L Weiner
Jul 1, 1990·The Journal of Clinical Endocrinology and Metabolism·A RabinovitchG L Warnock
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D I GottliebJ E Schwob
May 26, 1995·Science·J D KatzD Mathis
Dec 1, 1994·Journal of Autoimmunity·D R WegmannD Daniel
May 1, 1994·Clinical Immunology and Immunopathology·K J PennlineM Monahan
Oct 1, 1993·The Journal of Clinical Investigation·M A Atkinson, N K Maclaren
Apr 1, 1993·European Journal of Immunology·D Melamed, A Friedman

❮ Previous
Next ❯

Citations

Oct 27, 2004·Diabetologia·L MonetiniUNKNOWN Immunotherapy Diabetes (IMDIAB) group
Aug 4, 2001·The New England Journal of Medicine·A Davidson, B Diamond
Jun 26, 2003·DNA and Cell Biology·Alice F Li, Alan Escher
Feb 23, 2012·Cold Spring Harbor Perspectives in Medicine·Xavier Clemente-CasaresPere Santamaria
Jan 22, 2003·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·William E Winter, Desmond Schatz
Feb 8, 2014·Diabetes Management·Dan XuStephen D Miller
Feb 1, 2005·Annals of the New York Academy of Sciences·Berrin Ergun-LongmireNoel K Maclaren
Nov 3, 2010·Immunology·Jeffrey BabadTeresa P DiLorenzo
Feb 13, 2001·Cellular Immunology·G M WoodsH K Muller
Nov 3, 2020·World Journal of Diabetes·Rui-Feng MaoYe-Fu Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.